|
- The New England Journal of Medicine | Research Review Articles on . . .
The New England Journal of Medicine (NEJM) is a weekly general medical journal that publishes new medical research and review articles, and editorial opinion on a wide variety of topics of
- Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
Tirzepatide and semaglutide are highly effective medications for obesity management The efficacy and safety of tirzepatide as compared with semaglutide in adults with obesity but without type 2 di
- Zongertinib in Previously Treated - The New England Journal of Medicine
Innovative oral targeted therapies are warranted for patients with human epidermal growth factor receptor 2 (HER2)–mutant non–small-cell lung cancer (NSCLC) Zongertinib is an oral
- Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
Tarlatamab, a bispecific delta-like ligand 3–directed T-cell engager immunotherapy, received accelerated approval for the treatment of patients with previously treated small-cell lung cancer
- Encorafenib, Cetuximab, and mFOLFOX6 in - The New England Journal of . . .
First-line treatment with encorafenib plus cetuximab (EC) with or without chemotherapy (oxaliplatin, leucovorin, and fluorouracil [mFOLFOX6]) for BRAF V600E–mutated metastatic colorectal cancer
- Structured Exercise after Adjuvant Chemotherapy for Colon Cancer
In this phase 3, randomized trial conducted at 55 centers, we assigned patients with resected colon cancer who had completed adjuvant chemotherapy to participate in a structured exercise program
- New England Journal of Medicine
The New England Journal of Medicine publishes high-quality medical research, reviews, and opinions to advance medical science and improve patient care
- Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis
In a phase 3, randomized, controlled trial, we assigned adults with biopsy-proven active lupus nephritis in a 1:1 ratio to receive obinutuzumab in one of two dose schedules (1000 mg on day 1 and
|
|
|